Alkermes (ALKS) Non Operating Income (2010 - 2026)
Alkermes' (ALKS) quarterly Non Operating Income came in at -$13.6 million in Q1 2026, down 216.66% year-on-year from $11.7 million in Q1 2025, and down 700.35% on a QoQ basis from $2.3 million in Q4 2025.
Alkermes (ALKS) Non Operating Income (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Non Operating Income data on file, last reported at -$13.6 million in Q1 2026.
- On a quarterly basis, Non Operating Income fell 216.66% year-over-year to -$13.6 million in Q1 2026; TTM through Mar 2026 was $12.2 million, a 61.06% decrease from a year earlier, with the FY2025 full-year figure at $37.5 million, up 62.21% from the prior year.
- Non Operating Income for Q1 2026 stood at -$13.6 million, down from $2.3 million in the prior quarter.
- Over the last five years, Non Operating Income for ALKS reached as high as $11.9 million in Q2 2025 and fell as low as -$18.4 million in Q1 2022.
- Historically, Non Operating Income has averaged $1.7 million across 5 years, with a median of $3.5 million in 2023.
- Across the five-year window, Non Operating Income plunged 729.04% in 2022 and jumped 1120.71% in 2024, its largest moves.
- Year by year, Non Operating Income stood at -$1.1 million in 2022, then jumped by 433.18% to $3.7 million in 2023, then soared by 95.41% to $7.2 million in 2024, then sank by 68.43% to $2.3 million in 2025, then slumped by 700.35% to -$13.6 million in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were -$13.6 million in Q1 2026, $2.3 million in Q4 2025, and $11.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -7.50 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Alkermes | 8.78 Bn | 8.27 Bn | 331.33 Mn | -13.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.65 Mn |
| Dec 31, 2025 | 2.27 Mn |
| Sep 30, 2025 | 11.66 Mn |
| Jun 30, 2025 | 11.86 Mn |
| Mar 31, 2025 | 11.70 Mn |
| Dec 31, 2024 | 7.20 Mn |
| Sep 30, 2024 | 5.47 Mn |
| Jun 30, 2024 | 6.84 Mn |
| Mar 31, 2024 | 3.60 Mn |
| Dec 31, 2023 | 3.69 Mn |
| Sep 30, 2023 | 3.51 Mn |
| Jun 30, 2023 | 560,000.00 |
| Mar 31, 2023 | -361,000.00 |
| Dec 31, 2022 | -1.11 Mn |
| Sep 30, 2022 | -6.73 Mn |
| Jun 30, 2022 | 1.21 Mn |
| Mar 31, 2022 | -18.41 Mn |
| Dec 31, 2021 | -2.16 Mn |
| Sep 30, 2021 | -6.88 Mn |
| Jun 30, 2021 | 1.23 Mn |